Vertex Pharmaceuticals Inc. (VRTX)
NASDAQ:VRTX
Want to see VRTX full AI Analyst Report?
VRTX Stock Chart & Stats
$441.20
$0.48(0.12%)
At close: 4:00 PM EST
$441.20
$0.48(0.12%)
Day’s Range― - ―
52-Week Range$362.50 - $507.92
Previous CloseN/A
Volume295.43K
Average Volume (3M)1.20M
Market Cap
$107.89B
Enterprise Value$110.08B
Total Cash (Recent Filing)$7.25B
Total Debt (Recent Filing)$1.99B
Price to Earnings (P/E)24.9
Beta0.54
Next Earnings
Jul 30, 2026EPS Estimate
4.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)17.01
Shares Outstanding253,805,420
10 Day Avg. Volume1,399,434
30 Day Avg. Volume1,199,701
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)6.21
Price to Sales (P/S)9.60
P/FCF Ratio36.30
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue8.98
Enterprise Value/Gross Profit10.41
Enterprise Value/Ebitda21.23
Forecast
1Y Price Target
$562.91Price Target Upside27.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering25
EPS Forecast (FY)19.31
Revenue Forecast (FY)$13.04B
Bulls Say, Bears Say
Bulls Say
High Gross Margins And ProfitabilitySustained mid-80% gross margins and strong operating/net margins indicate durable pricing power and efficient product economics for Vertex’s therapies. High margins support long-term R&D funding, commercial expansion and shareholder returns, providing structural earnings resilience beyond quarter-to-quarter swings.
Strong Cash Position And Cash GenerationA $13 billion cash/investment balance plus recovering free cash flow gives Vertex durable financial flexibility to fund pipelines, commercial launches, buybacks, and unexpected setbacks. Low leverage amplifies optionality for partnerships or acquisitions without forcing dilutive financing over the medium term.
Revenue Diversification Via Non-CF LaunchesEmerging revenue from KASJEVY and GERNAVICS and a stated $500M+ non-CF target signal a structural move to reduce CF concentration. Successful commercialization of new franchises would broaden the revenue base, lower single-franchise risk and provide multiple, longer-term growth vectors beyond CF.
Bears Say
Concentration In Cystic Fibrosis FranchiseA continued heavy reliance on CFTR modulators leaves Vertex exposed to payer pricing pressure, label-eligibility ceilings and any CF-specific competitive or patent risks. Structural revenue concentration raises stakes on successful geographic expansion and on-time lifecycle management for CF products.
Evidence Of Cash/profit Volatility And R&D SetbacksThe 2024 operating and free cash flow swing plus program discontinuations show durable execution and development risk in biopharma. Large R&D investments can yield step-function setbacks that pressure margins and delay diversification, requiring sustained cash buffers to absorb future surprises.
Regulatory/outcome Risk For Key Pipeline ReadoutsSeveral high-impact approvals depend on longer-term renal outcomes and pivotal readouts. Regulatory timing and uncertain efficacy durability are structural risks: unfavorable or delayed outcomes could materially limit market access, commercialization timelines and the expected non-CF revenue diversification.
Vertex Pharmaceuticals News
VRTX FAQ
What was Vertex Pharmaceuticals Inc.’s price range in the past 12 months?
Vertex Pharmaceuticals Inc. lowest stock price was $362.50 and its highest was $507.92 in the past 12 months.
What is Vertex Pharmaceuticals Inc.’s market cap?
Vertex Pharmaceuticals Inc.’s market cap is $107.89B.
When is Vertex Pharmaceuticals Inc.’s upcoming earnings report date?
Vertex Pharmaceuticals Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 56 days.
How were Vertex Pharmaceuticals Inc.’s earnings last quarter?
Vertex Pharmaceuticals Inc. released its earnings results on May 04, 2026. The company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.243 by $0.227.
Is Vertex Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Vertex Pharmaceuticals Inc.’s price is currently Undervalued.
Does Vertex Pharmaceuticals Inc. pay dividends?
Vertex Pharmaceuticals Inc. does not currently pay dividends.
What is Vertex Pharmaceuticals Inc.’s EPS estimate?
Vertex Pharmaceuticals Inc.’s EPS estimate is 4.72.
How many shares outstanding does Vertex Pharmaceuticals Inc. have?
Vertex Pharmaceuticals Inc. has 253,805,420 shares outstanding.
What happened to Vertex Pharmaceuticals Inc.’s price movement after its last earnings report?
Vertex Pharmaceuticals Inc. reported an EPS of $4.47 in its last earnings report, beating expectations of $4.243. Following the earnings report the stock price went down -1.277%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in VRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vertex Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$562.91 (27.59% Upside)
$562.91 (27.59% Upside)
Blogger Sentiment
Bullish
VRTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 265.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Bearish
Bullish news 33%
Bearish news 67%
Bearish news 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.56%
12-Months-Change
Fundamentals
Return on Equity
23.93%
Trailing 12-Months
Asset Growth
15.75%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
VRTX Company Deck
VRTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed a positive, execution-focused tone: strong top-line results (8% revenue growth to $2.99B), major commercial milestones (AlifTrack >$1B cumulative revenue, >1M Gernavix prescriptions, >500 KASJEVY patients initiated), and a standout Phase III interim win for povitacicept in IgAN with rapid BLA submission. At the same time, the company disclosed a program discontinuation (VX-522) due to tolerability, increased SG&A (30% YoY) tied to commercialization investments, and several important longer-term readouts (eGFR for renal programs, enaxaplin and AMPLITUDE results) remain pending. The positives — strong revenue and multiple high-impact pipeline/regulatory achievements — outweigh the challenges and near-term variability risks.View all VRTX earnings summariesVRTX Revenue Breakdown
85.93% TRIKAFTA/KAFTRIO
6.98% ALYFTREK
6.83% Other product revenues
0.26% Other revenues
VRTX Stock 12 Month Forecast
Average Price Target
$562.91
▲(27.59% Upside)
Technical Analysis
Ownership Overview
0.21% Insiders
35.96% Mutual Funds
33.16% Other Institutional Investors
1.67% Public Companies and Individual Investors